- WHO: The 2022 recommended influenza strains in southern hemisphere
- New COVID-19 variant: ETA appeared in at least 82 countries and regions
- Tumor microenvironment and drug resistance in immunotherapy
- Can Probiotics prevent Alzheimer’s disease as regulator of brain function?
- The nano antibody from alpaca effectively against COVID-19 and variants
- COVID-19 can’t escape by the new method of virus detection: DNA sensor
Multi-center study for treating congenital heart disease with stem cells
- Science: Scientists have broken through CO₂ synthetic starch technology!
- Can you complete mRNA COVID-19 vaccination by eating vegetable salad?
- What COVID-19 vaccines does CDC accept if foreigners enter U.S.?
- WHO chief scientist: Soumya Swaminathan may face death penalty charges?
- Israel new drug for COVID-19: EXO-CD24 can reduce deaths by 50%
Multi-center study for treating congenital heart disease with stem cells.
Recently, Mott Children’s Hospital of the University of Michigan Health Center in the United States announced the launch of stem cell therapy for infants with single-ventricular heart disease. This is a multi-center study that focuses on children with left heart dysplasia syndrome. The institution owns the largest congenital heart disease program in the United States and is one of the first research sites to begin applying stem cell therapy to infants with single ventricular heart disease.
This multi-center randomized trial was jointly carried out by four clinical hospitals including Mott Children’s Hospital and led by the University of Miami and Lurie Children’s Hospital in Chicago. The subjects were randomly selected into the stem cell group or control group. The stem cell treatment group received autologous stem cell injections, and the control group received conventional surgical treatment. Finally, the results of patients who received stem cell therapy and those who did not receive stem cell therapy were compared.
The stem cells are extracted during the first heart surgery after the child is born. In the child’s second repair operation four to six months later, the pediatric cardiac surgeon injects stem cells into the child’s heart. All children will receive blood tests, echocardiography and magnetic resonance imaging follow-up for at least one year to evaluate the safety and effectiveness of stem cell therapy.
Complex congenital heart disease: a difficult disease
Left heart dysplasia syndrome is one of the most complex forms of congenital heart disease, occurring in approximately 9% of children with congenital heart defects. Surgery is currently the only treatment for this complex congenital heart disease, but over time, patients will develop heart failure that cannot be prevented and treated.
At this time, for these children, the only feasible way is a heart transplant. However, heart transplantation is restricted by the source of donors, immune rejection, cost and other issues. The mortality rate of infants with this disease in the first year after birth is as high as 25-35%. A study  showed that at the age of six, children with the most complicated congenital heart disease had worse behavior, function and quality of life than their peers without heart disease. Therefore, it is urgent to develop new therapies to deal with this complex congenital heart disease.
Stem cells: a new hope for complex congenital diseases
Stem cells are believed to release healing proteins, stimulate the heart to repair defective myocardium, prevent deterioration of heart function, and strengthen the normal working right ventricle while the heart is still developing.
Dr. Richard Ohyi, director of cardiac surgery at the hospital and co-director of the Congenital Heart Center, said: “Studies have shown that stem cell therapy may have the potential to strengthen and improve heart function in children who have no other treatment options. We hope this research It can provide more evidence for stem cell regenerative medicine to treat children with congenital heart disease.”
Complex congenital heart disease is currently very difficult to treat, and traditional surgical treatment is not effective. Regenerative medicine therapies led by stem cells are currently being applied to the treatment of congenital heart disease.
At present, hospitals such as the above-mentioned Mott Children’s Hospital have successively carried out clinical trials of stem cells to treat complex congenital heart diseases to evaluate their safety and effectiveness. In the future, more research is needed, and larger-scale multi-center clinical trials are carried out to provide higher-level evidence to accelerate the advancement of stem cell therapy to achieve clinical applications as soon as possible!
In fact, stem cells have been extensively studied in the field of cardiovascular diseases. Previously, the “First Time” column reporter stated in a direct G20 special report: If there is a problem with the heart, the heart cell patch can be directly attached to the heart during the operation to complete the work of heart repair. This technology will be realized in the near future. Stem cell-based “heart regeneration therapy” and “heart patch” are increasingly entering the public’s field of vision. In the future, this type of technology is expected to become a new choice for cardiac surgery.
 Goldberg CS, Hu C, Brosig C, Gaynor JW, Mahle WT, Miller T, Mussatto KA, Sananes R, Uzark K, Trachtenberg F, Pizarro C, Pemberton VL, Lewis AB, Li JS, Jacobs JP, Cnota J, Atz AM, Lai WW, Bellinger D, Newburger JW; PHN INVESTIGATORS. Behavior and Quality of Life at 6 Years for Children With Hypoplastic Left Heart Syndrome. Pediatrics. 2019 Nov;144(5):e20191010.
(source:internet, reference only)